Loading...
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
Although Fingolimod is registered as a second-line drug in relapsing-remittend multiple sclerosis (RRMS) in Europe there are no clinical studies available comparing Fingolimod (FTY) and Natalizumab (N). This observational cohort-study used health data routinely collected in outpatient neurology prac...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Berlin Heidelberg
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3843369/ https://ncbi.nlm.nih.gov/pubmed/24008757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-013-7082-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|